SOURCE: Organetix, Inc.

June 06, 2005 09:15 ET

Organetix, Inc. Announces Success in Relieving the Side Effects of Chemotherapy on a Lung and Liver Cancer Patient

In Addition to Treating Hepatitis C, the Company's A4+L Liver Product May Be Useful in Treating Chemotherapy Patients

NEW YORK, NY -- (MARKET WIRE) -- June 6, 2005 -- Organetix, Inc. http://www.organetixinc.com (OTC BB: OGTX) announced today that it has received positive independent medical and laboratory results from a test conducted in Peru on a chemotherapy patient diagnosed with lung cancer and metastasis on the liver.

This patient received our A4+L liver product while taking her 5th through to her 32nd treatment of chemotherapy.

After 15 days of taking A4+L along with her chemotherapy treatments, her nausea and fatigue disappeared completely and her appetite was restored. She recorded a weight gain of 7 kilograms.

Brad Clarke, President and CEO of Organetix, Inc., stated, "These independent medical and laboratory results support management's view that the A4+L Liver Product may also become an adjunct product to chemotherapy and interferon drugs. We will now plan to do a large placebo-controlled clinical study on chemotherapy and interferon patients."

About Organetix, Inc.

Organetix, Inc. (www.organetixinc.com) is a biotechnology company that is in the process of treating patients with a unique nutraceutical that appears to relieve symptoms of Hepatitis C. Organetix has the exclusive worldwide rights for this nutraceutical product. Hepatitis C is a life-threatening, blood-borne, liver disease that is caused by a virus. It is estimated that millions of individuals worldwide are infected with Hepatitis C, making it one of the greatest public health threats faced in recent years.

Statements contained in this press release, which are not historical facts, are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based largely on the Company's expectations and are subject to a number of risks and uncertainties beyond the Company's control, including but not limited to economic, competitive and other factors affecting the Company's operations, management team effectiveness, expansion strategies, available financing, market prices and recovery costs, government regulations involving the Company, facts and events not known at the time of this release, and other factors discussed in the Company's filings with the Securities and Exchange Commission.

These statements are not guarantees of future performance and readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update publicly any forward-looking statements.

Contact Information

  • Contact:
    Corporate Communications Group, Inc.
    David Pomerantz
    516-791-0000 ext. 102
    david@ccgnewyork.com